BiondVax Pharmaceuticals plans to sell $9 million of ADSs in IPO

Bookrunner Aegis Capital helps sells ADSs representing ordinary shares

By Devika Patel

Knoxville, Tenn., April 10 – BiondVax Pharmaceuticals Ltd. will raise about $9 million in its initial public offering of American Depositary Shares representing ordinary shares with a 15%, 45-day greenshoe, according to an FWP filed Friday with the Securities and Exchange Commission. The deal was announced Dec. 30.

Aegis Capital Corp. is the bookrunner.

Proceeds will be used for clinical studies, working capital and general corporate purposes.

The clinical-stage biopharmaceutical company is based in Nes Ziona, Israel. The company has applied to list the ADSs on the Nasdaq under the symbol “BVXV.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.